Bioniche Life Scienc (BNHLF) 0.1690 $BNHLF
Global Animal Growth Promoters and Performance Enhancers Market Opportunities, 2018: Antibiotics, Growth Hormones, Feed Enzymes, Organic Acids, Probiotics and Prebiotics, Agonists & Phytogenics
M2 - Thu May 08, 2:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34fcd2/animal_growth) has announced the addition of the "Global Animal Growth Promoters and Performance Enhancers Market Opportunities, 2018: Antibiotics, Growth Hormones, Feed Enzymes, Organic Acids, Probiotics and Prebiotics, Agonists & Phytogenics" report to their offering. The global animal growth promoters market was valued at $6,871.6 million in 2013 and is expected to reach $8,787 million by 2018, growing at a CAGR of 5% from 2013 to 2018 The antibiotic growth promoters commanded the largest share of the global animal growth promoters market in 2013. However, the feed enzymes market is likely to grow at a highest CAGR in the forecast period (2013-2018). Over the years, the global demand for animal meat is increasing significantly. In order to meet the growing demand, they are widely being used in the animal feed. The pivotal factors driving the meat demand is the enormous surge in population, urbanization, and increase in gross domestic product per capita in developing countries. The global animal growth promoters market is categorized into eight broad segments, namely, antibiotics, probiotics and prebiotics, organic acids, phytogenics, ?-agonists, hormonal growth promoters, feed enzymes, and others. Based on the animals, the animal growth promoters market comprises of porcine, poultry, livestock equine, aquaculture and others. They are used in animal feed to increase the weight of the animals and to promote faster growth. The use of growth promoters results in a direct decrease in the production cost of meat; by decreasing the amount of high cost natural feed. In addition, the use of growth promoters decreases the amount of resources required, which brings down the cost of the animal meat ultimately. The risk of loss to epidemic outbreaks is prompting the producers to make use of growth promoters and performance enhancers. Thus the demand for is likely to continue owing to the increasing prices of resources such as feed, water, land, and increasing epidemic outbreaks in animals. The key players in the animal growth promoters market are: - Bayer Animal Health (A Subsidiary of Bayer Ag) - Biomin Holding Gmbh - Bioniche Animal Health (A Division of Bioniche Life Sciences, Inc.) - Boehringer Ingelheim - Bupo Animal Health (PTY) - Cargill, Inc. - Elanco Animal Health (A Division of Eli Lilly and Company) - Merck Animal Health (A Subsidiary of Merck & Co., Inc.) - Royal Dsm N.V. - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/34...mal_growth
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business
PR Newswire - Mon Apr 14, 8:50AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that its shareholders have voted in favour of the sale of the Company's Animal Health business to Vétoquinol SA.
Bioniche Life Sciences Inc. Continues to Execute on Strategic Review
PR Newswire - Thu Apr 03, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it has successfully monetized two non-core properties for net proceeds in excess of $1 million.
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction
PR Newswire - Thu Apr 03, 10:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that Institutional Shareholder Services (ISS) has recommended that shareholders vote FOR the special resolution pertaining to the sale of all of the Corporation's Animal Health business to Vétoquinol SA, to be considered at the upcoming Special Meeting of Shareholders:
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast
PR Newswire - Thu Mar 13, 5:06PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:56AM CST
Trading resumes in:
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:11AM CST
The following issues have been halted by IIROC:
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. Delisting Approved by the ASX
PR Newswire - Wed Dec 11, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC, ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announces that the Australian Securities Exchange (ASX) has approved the Company's application to delist from the official list of the ASX subject to certain usual conditions.
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada
PR Newswire - Wed Dec 04, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a study approved for publication in the Journal of Food Protection demonstrates that Verotoxigenic Escherichia coli (VTEC) results in a cost of $403.9 million per year in Canada related to primary infections and long-term health outcomes. More than 93% of the VTEC infections are caused by the O157 strain of E. coli, and Bioniche One Health has developed a cattle vaccine to reduce the burden of this pathogen.
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.
PR Newswire - Sun Dec 01, 4:00PM CST
a purified hyaluronate sodium I.V./I.A. product for horses-
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
Bioniche Founder and CEO Announces his New Role with the Company
PR Newswire - Wed Sep 11, 11:03AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today issued an open letter to all shareholders from Founder, President & CEO, Graeme McRae, regarding his going forward role with the Company:
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Animal Growth Promoters and Performance Enhancers Market Opportunities, 2018: Antibiotics, Growth Hormones, Feed Enzymes, Organic Acids, Probiotics and Prebiotics, Agonists & Phytogenics
M2 - Thu May 08, 2:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34fcd2/animal_growth) has announced the addition of the "Global Animal Growth Promoters and Performance Enhancers Market Opportunities, 2018: Antibiotics, Growth Hormones, Feed Enzymes, Organic Acids, Probiotics and Prebiotics, Agonists & Phytogenics" report to their offering. The global animal growth promoters market was valued at $6,871.6 million in 2013 and is expected to reach $8,787 million by 2018, growing at a CAGR of 5% from 2013 to 2018 The antibiotic growth promoters commanded the largest share of the global animal growth promoters market in 2013. However, the feed enzymes market is likely to grow at a highest CAGR in the forecast period (2013-2018). Over the years, the global demand for animal meat is increasing significantly. In order to meet the growing demand, they are widely being used in the animal feed. The pivotal factors driving the meat demand is the enormous surge in population, urbanization, and increase in gross domestic product per capita in developing countries. The global animal growth promoters market is categorized into eight broad segments, namely, antibiotics, probiotics and prebiotics, organic acids, phytogenics, ?-agonists, hormonal growth promoters, feed enzymes, and others. Based on the animals, the animal growth promoters market comprises of porcine, poultry, livestock equine, aquaculture and others. They are used in animal feed to increase the weight of the animals and to promote faster growth. The use of growth promoters results in a direct decrease in the production cost of meat; by decreasing the amount of high cost natural feed. In addition, the use of growth promoters decreases the amount of resources required, which brings down the cost of the animal meat ultimately. The risk of loss to epidemic outbreaks is prompting the producers to make use of growth promoters and performance enhancers. Thus the demand for is likely to continue owing to the increasing prices of resources such as feed, water, land, and increasing epidemic outbreaks in animals. The key players in the animal growth promoters market are: - Bayer Animal Health (A Subsidiary of Bayer Ag) - Biomin Holding Gmbh - Bioniche Animal Health (A Division of Bioniche Life Sciences, Inc.) - Boehringer Ingelheim - Bupo Animal Health (PTY) - Cargill, Inc. - Elanco Animal Health (A Division of Eli Lilly and Company) - Merck Animal Health (A Subsidiary of Merck & Co., Inc.) - Royal Dsm N.V. - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/34...mal_growth
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business
PR Newswire - Mon Apr 14, 8:50AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that its shareholders have voted in favour of the sale of the Company's Animal Health business to Vétoquinol SA.
Bioniche Life Sciences Inc. Continues to Execute on Strategic Review
PR Newswire - Thu Apr 03, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it has successfully monetized two non-core properties for net proceeds in excess of $1 million.
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction
PR Newswire - Thu Apr 03, 10:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that Institutional Shareholder Services (ISS) has recommended that shareholders vote FOR the special resolution pertaining to the sale of all of the Corporation's Animal Health business to Vétoquinol SA, to be considered at the upcoming Special Meeting of Shareholders:
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast
PR Newswire - Thu Mar 13, 5:06PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:56AM CST
Trading resumes in:
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:11AM CST
The following issues have been halted by IIROC:
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. Delisting Approved by the ASX
PR Newswire - Wed Dec 11, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC, ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announces that the Australian Securities Exchange (ASX) has approved the Company's application to delist from the official list of the ASX subject to certain usual conditions.
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada
PR Newswire - Wed Dec 04, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a study approved for publication in the Journal of Food Protection demonstrates that Verotoxigenic Escherichia coli (VTEC) results in a cost of $403.9 million per year in Canada related to primary infections and long-term health outcomes. More than 93% of the VTEC infections are caused by the O157 strain of E. coli, and Bioniche One Health has developed a cattle vaccine to reduce the burden of this pathogen.
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.
PR Newswire - Sun Dec 01, 4:00PM CST
a purified hyaluronate sodium I.V./I.A. product for horses-
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
Bioniche Founder and CEO Announces his New Role with the Company
PR Newswire - Wed Sep 11, 11:03AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today issued an open letter to all shareholders from Founder, President & CEO, Graeme McRae, regarding his going forward role with the Company:
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
